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ABSTRACT
Objective: To create clinical normative data tables for Norwegian patients with schizophrenia
spectrum disorders, to examine whether clinical normative data from Norway differs from similar
normative data from Canada and the U.S., and to illustrate the usefulness of such data.
Method: A nationally representative sample of 335 patients from psychiatric hospitals in Bergen,
Norway was included. Inclusion criteria were 18–39 years of age, Norwegian as first language, and
symptoms of schizophrenia, psychosis, or hallucinations. Comorbid substance abuse was recorded
in 134 (40.0%). All completed the Norwegian version of the Repeatable Battery for the Assessment
of Neuropsychological Status (RBANS).
Results: The average scores of patients with schizophrenia spectrum disorders were approximately
one to two standard deviations below the mean for healthy adults. There were no significant dif-
ferences in scores between patients with or without comorbid substance abuse. Men had higher
scores than women. Clinical normative reference value look-up tables were created.
Conclusions: Clinical normative values were very similar to values from Canada and the U.S.
Clinical normative data, as a supplement to standard healthy normative data, can be used to
describe patients’ cognitive performance in terms of expectation for their peer group which can
be useful for multidisciplinary treatment planning.
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People with schizophrenia spectrum disorders usually
experience cognitive impairments (Anda et al., 2016; Barder
et al., 2013; Dickerson et al., 2004; Gogos, Joshua, & Rossell,
2010; Helle et al., 2014; Hobart, Goldberg, Bartko, & Gold,
1999; Iverson, Brooks, & Haley, 2009; Keefe, 2014; Øie,
Sundet, & Ueland, 2011; Sponheim et al., 2010; Wilk et al.,
2004; Zhang et al., 2012, 2018). On average, they perform
one to two standard deviations below the general population
on tests of attention (Holmen, Juuhl-Langseth, Thormodsen,
Melle, & Rund, 2010), learning and memory (Barder et al.,
2013; Egeland et al., 2003), processing speed (Schaefer,
Giangrande, Weinberger, & Dickinson, 2013), and executive
functioning (Reichenberg et al., 2010). Cognitive impairment
in people with schizophrenia spectrum disorders is associ-
ated with worse outcomes, such as decreased quality of life,
unemployment, poorer social functioning, and institutional-
ization (Lysaker, Bryson, Davis, & Bell, 2005; Øie et al.,
2011; Rajji, Miranda, & Mulsant, 2014; Rosenheck et al.,
2006; Savilla, Kettler, & Galletly, 2008; Vaskinn et al., 2008).
The severity of cognitive impairment is somewhat correlated
with disease duration (Barder et al., 2013; Keefe, 2014; Rajji
et al., 2014; Sponheim et al., 2010; Zhang, Li et al., 2015)
and disease severity (Barder et al., 2013; Galaverna, Morra,
& Bueno, 2014; Simonsen et al., 2011).
Comorbid substance abuse is common among people
with schizophrenia spectrum disorders. In Norway, the over-
all prevalence rate of substance abuse among patients with
schizophrenia spectrum disorders is estimated to be 25–38%
(Nesvåg et al., 2015; Ringen et al., 2007). The effect of sub-
stance abuse on cognition in schizophrenia spectrum disor-
ders is not well understood. Current findings range from
worse cognition, no difference, or better cognition among
those patients abusing substances compared to those not
abusing (Potvin, Stavro, & Pelletier, 2012).
It is common for people with schizophrenia spectrum
disorders to undergo neuropsychological screening evalua-
tions to document the nature and severity of their cognitive
deficits. This information can be important for treatment
planning (Spaulding et al., 1999). In addition, the nature
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and severity of cognitive deficits have implications for edu-
cational and vocational planning (Hoffmann, Kupper,
Zbinden, & Hirsbrunner, 2003). When assessing the nature
and severity of cognitive deficits, clinical normative data is
particularly useful because it allows clinicians to describe
patients’ cognitive performance in terms of how they are
functioning in comparison to other people with schizophre-
nia spectrum disorders (Iverson et al., 2009; Peria~nez et al.,
2007; Wilk et al., 2004). For example, a person with schizo-
phrenia could perform very poorly compared to the stand-
ard healthy normative data but perform normally or even
above expectations in comparison to other people with
schizophrenia (using clinical normative data for compari-
son). Knowing this information might facilitate more tar-
geted and personalized psychosocial rehabilitation planning
(McGurk, Mueser, DeRosa, & Wolfe, 2009).
The Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS) is commonly used in
research and clinical practice with people with schizophrenia
(De la Torre, Perez, Ramallo, Randolph, & Gonzalez-Villegas,
2016; Dickerson et al., 2004; Gogos et al., 2010; Harris et al.,
2004; Helle et al., 2014; Hobart et al., 1999; Iverson et al.,
2009; Loughland, Lewin, Carr, Sheedy, & Harris, 2007; Tucker
& Bertke, 2019; Wang et al., 2019; Wilk et al., 2004; Zhang,
Han et al., 2015; Zhang, Li et al., 2015; Zhang et al., 2012).
Two prior studies have provided clinical normative data for
the RBANS in people with schizophrenia disorders, one in the
United States (Wilk et al., 2004) and one in Canada (Iverson
et al., 2009). The purpose of this paper is to illustrate the
importance and usefulness of clinical normative data for peo-
ple with severe and persistent mental illness. Further, we will
compare the clinical normative data for the RBANS reported
by Iverson et al. (2009) to clinical normative data derived
from the current sample, applying identical statistical proce-
dures and presentation of results. We predict that the
Norwegian clinical normative values will be fairly similar to
those published by Iverson et al. (2009).
Method
Participants
This study uses anonymous data from a clinical sample of
335 patients, referred for neuropsychological assessment
from psychiatric inpatient hospitals in Bergen, Norway. The
study was evaluated by the Regional Committee for Medical
and Health Research Ethics, and by the regional Data
Protection Official on behalf of the Norwegian Data
Protection Authority (DPA), which is the legislative author-
ity for The Personal Data Act in Norway. Approval from
the DPA was granted January 13, 2017. Inclusion criteria
were 18–39 years of age, Norwegian as their first language,
and symptoms of schizophrenia, psychosis, or hallucinations.
Patients with psychotic symptoms due to known affective
disorders were excluded (n¼ 36). Patients of immigrant
parents were included if born and educated in Norway, but
race or ethnicity were not recorded. Patients not born or
educated in Norway were excluded (n¼ 24). Comorbid sub-
stance abuse was recorded in 134 (40.0%). Type and
duration of substances abused were not recorded, but most
substance abusing patients were long-time polysubstance
abusers. Patients at the time of testing were usually in the
process of undergoing differential diagnostic evaluations
during their hospitalization. We found 323 registered diag-
noses classified according to The International Statistical
Classification of Diseases and Related Health Problems–10
(World Health Organization, 2004). The majority of patients
had diagnoses of schizophrenia disorders (F20.0–F20.9) and
schizoaffective disorders (F25.0–F25.9), accounting for
48.1%. Of those, 49.7% had F20.0 paranoid schizophrenia,
26.5% had schizoaffective disorders, and 23.9% had either
undifferentiated schizophrenia (F20.3), simple schizophrenia
(F20.6) or schizophrenia, unspecified (F20.9). Acute psych-
osis was diagnosed in 16.5% (F22.0–F23.9). Psychotic dis-
order due to substance abuse (F1x.5) was diagnosed in
16.1%. Unspecified nonorganic psychosis (F29) was diag-
nosed in 12.1%. A minority were awaiting diagnostic deci-
sion (10.9%), having a diagnosis of hallucinations
(R44.0–44.8) or strange and inexplicable behavior (R46.2).
The subjects ranged between 18–38 years in age, with a
mean age of 24.17 years (SD¼ 4.92). Years of education
ranged from 9–18 years, with a mean of 12.29 years
(SD¼ 1.83). There were more men than women, 208
(62.1%) and 127 (37.9%), respectively.
In Norway, government-funded mental health clinics offer-
ing inpatient and outpatient treatment are available across the
country. All treatment facilities are under the same legislation,
follow national guidelines for assessment and treatment of
mental illnesses, and report to mandatory national health
registries. When comparing the current sample with that of a
national registry-based prevalence study of substance abuse
and mental illness (Nesvåg et al., 2015), we find similar rates
of schizophrenia spectrum diagnosis, substance abuse, and
sex-ratio to the overall schizophrenia spectrum patient popu-
lation in Norway. For example, the difference between the
present sample and the national registry in sex-ratio is less
than 3%, for substance abuse it is less than 8%, and for ICD-
10 diagnosis F20 Schizophrenia it is less than 6%.
Measures
All patients completed the Norwegian version of the Repeatable
Battery for the Assessment of Neuropsychological Status
(RBANS; Randolph, 2013) as part of a routine clinical assess-
ment. This adult screening battery takes 20–40minutes to
administer. Five age-corrected Index scores with a mean score
of 100 and a standard deviation of 15 are obtained (Immediate
Memory, Visuospatial/Constructional, Language, Attention,
and Delayed Memory), as well as a Total Scale. The Norwegian
version of RBANS applies Scandinavian norms, matched to the
population statistics of 2012 in Denmark, Norway, and Sweden
(Randolph, 2013, p. 27). It is based on the U.S. version pub-
lished in 1998 (Randolph, 1998), and has two alternative forms
(A and B), whereas the current U.S. version has four forms
(Randolph, 2012). The translations are described in the manual
(Randolph, 2013, manual, pp. 8–9), and they were conducted
as recommended in the International Test Commission
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Guidelines for Translating and Adapting Tests (Gudmundsson,
2009). A detailed review of differences in instructions, scoring,
and normative data is presented in Raudeberg, Iverson, &
Hammar (2019).
Statistical analyses
Each patient was administered the RBANS using the standar-
dized procedure in the Norwegian version of the manual
(Randolph, 2013). Form A was administered to 183 (54.6%),
Form B to 152 (45.4%). Index scores were calculated using
Scandinavian norms for the age group 20–39 years, because
applying U.S norms have been shown to overestimate cogni-
tive functions in Norwegian patients with schizophrenia spec-
trum disorders (Raudeberg et al., 2019). A subset of the
participants (n¼ 208) completed the Norwegian research ver-
sion of the National Adult Reading Test (NART), which pro-
vides age and education adjusted measures of estimated
premorbid IQ (Sundet & Vaskinn, 2008). They had a mean
estimated premorbid Full Scale IQ (FSIQ) of 100.49
(SD¼ 4.43, Range ¼ 90–117). The majority (79.8%) had esti-
mated FSIQ scores in the range of 95–105 points, 8.7% had an
estimated FSIQ < 95. Some participants (n¼ 84) completed
the Norwegian version of the Wechsler Adult Intelligence
Scale Fourth Edition (Wechsler, 2011). They had a mean
WAIS-IV Full Scale IQ (FSIQ) of 84.52 (SD¼ 12.73, Range ¼
62–118). Descriptive statistics (e.g. mean, median, standard
deviation, interquartile range, skewness, and kurtosis) for the
age-adjusted RBANS Index standard scores were computed
for the entire sample, by comorbid substance abuse (yes/no),
by levels of educational attainment (less than high school,
high school, and more than high school), and by gender.
The clinical normative data was computed using fre-
quency analysis tables stratified by the above-mentioned
groups. RBANS Index scores are presented based on
Wechsler-Benton classifications, commonly used in neuro-
psychology, including: extremely low ( 2nd percentile),
unusually low (3rd–9th percentiles), low average (10th–24th
percentiles), average (25th–75th percentiles), high average
(76th–90th percentiles), and superior ( 91st percentile).
The prevalence of low scores was calculated by simultan-
eously examining all five RBANS index scores (Immediate
Memory, Visuospatial/Constructional, Language, Attention,
and Delayed Memory), rather than performance on each
domain in isolation. The base rates of low domain scores
were calculated by using four cutoff scores that might be
routinely used in clinical practice, including: (a) more than
one standard deviation (SD) below the mean (i.e. < 85), (b)
below the 10th percentile (i.e. < 81), (c) at or below the 5th
percentile (i.e.  76), and (d) more than two SDs below the
mean (i.e. < 70). The prevalence of low scores is presented
for the entire sample, by gender, by comorbid substance
abuse (yes/no), by levels of educational attainment (less than
high school, high school, and more than high school), by
NART estimated FSIQ (i.e. less than 100 or 100 and higher),
and by WAIS-IV Full Scale IQ (i.e. less than 80 or 80 and
higher) in the subsample that underwent the more compre-
hensive evaluation.
Results
As seen in Table 1, the mean scores across the sample were
one to two standard deviations below the mean for healthy
adults. Notice that the average scores (i.e. at the 50th per-
centile) for patients with schizophrenia spectrum disorders
are as follows: Immediate Memory Index ¼ 78,
Visuospatial/Constructional Index ¼ 90, Language Index ¼
78, Attention Index ¼ 70, Delayed Memory Index ¼ 80,
and Total Scale ¼ 69.
There were no significant differences when comparing
index scores for substance abusers with those not abusing
substances (p-values ranging from 0.28–0.89). Men had sig-
nificantly higher scores on the Immediate Memory Index,
Visual/Constructional Index, and the Total Scale compared
to women. Effect sizes were small (Cohen’s d¼ 0.30,
d¼ 0.37, and d¼ 0.29, respectively). Years of education were
significantly correlated (p< .001) with all index scores and
Total Scale scores (rs ranged from 0.23–0.39). A one-way
analysis of variance (ANOVA) revealed that there were sig-
nificant main effects for education for all five Index scores
and the Total Scale score. Patients with more than high
school education performed significantly better on every
Index score and the Total Scale score compared to patients
with less than high school. They also performed better than
those with high school education on Immediate Memory,
Language, and Attention Indexes, and the Total Scale. There
were no significant differences between patients that had
completed high school and those who had not. Patients with
higher NART estimated premorbid FSIQ and higher WAIS-
IV FSIQ performed significantly better (p-values ranging
from 0.009–<0.001) on all Indexes and the Total Scale
score. Comparing patients with IQs lower than 80 with
patients with IQs of 80 or higher, we found medium to large
effect sizes for all Indexes (Immediate Memory: d¼ 0.64,
Visuospatial/Constructional: d¼ 0.73, Language: d¼ 0.86,
Attention: d¼ 0.90, Delayed Memory: d¼ 0.88, and Total
Scale: d¼ 1.13).
The interpretive classifications for the clinical normative
data are presented in Table 2. Using the descriptive classifi-
cations (and corresponding percentile range) of extremely
low ( 2nd percentile), unusually low (3rd–9th percentiles),
low average (10th–24th percentiles), average (25th–75th per-
centiles), high average (76th–90th percentiles), and superior
( 91st percentile), clinicians can see how a patient’s per-
formance on the RBANS Indexes compares to other patients
with schizophrenia spectrum disorders. For example: (1) a
Delayed Memory Index score of 50 is extremely low for
healthy adults, but is low average for patients with schizo-
phrenia spectrum disorders; (2) an Attention Index of 75 is
unusually low for healthy adults, but average for younger
patients with schizophrenia spectrum disorders; and (3) an
Immediate Memory Index of 100 is average for healthy
adults but superior for patients with schizophrenia spectrum
disorders with less than high school education. Consider
also that a score of 50 on the RBANS Total Scale, which
later improves to a score of 69 at reassessment after
inpatient treatment and a medication change, would con-
tinue to be extremely low for healthy individuals, but would
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move a patient with schizophrenia spectrum disorder from
low average to average; an improvement that would not be
readily apparent when using standard normative tables.
The prevalence of low scores is presented in Table 3 for
the entire sample, by gender, by levels of educational attain-
ment (less than high school, high school, and more than
high school), by NART estimated Full Scale IQ (i.e. less
than 100 or 100 and higher), and by WAIS-IV Full Scale IQ
(i.e. less than 80 or 80 and higher). In the entire sample,
79.1% had two or more index scores below one SD, 63.3%
had two or more at or below the 5th percentile, and 40.0%
had two or more index scores below two SDs. The base rates
of low scores varied by education. In this sample, 86.7% of
the patients with less than high school education, 79.4%
of the patients with high school education, and 57.7% of
patients with more than high school education had two or
more index scores one or more SDs below the mean [v2
(2)¼ 26.50, p< .001, V¼ 0.281]. Regarding frankly impaired
scores, 50.5% of the patients with less than high school edu-
cation, 30.9% of the patients with high school education,
and 19.7% of patients with more than high school education
had two or more index scores two SDs below the mean [v2
(2)¼ 23.55, p< .001, V¼ 0.265].
Higher base rates of low scores were also more common
in those people with lower intellectual abilities. In patients
with NART FSIQ scores below 100, 91.4% obtained two or
more low scores (i.e. < 1 SD), whereas patients with NART
FSIQ scores 100 or higher, 73.9% obtained two or more
scores < 1 SD [v2 (1)¼10.53, p¼ .002, /¼0.25]. In
patients with NART FSIQ scores below 100, 51.1% obtained
two or more frankly impaired index scores (i.e. < 2 SDs)
compared to 27.8% of patients with NART FSIQ scores 100
or higher [v2 (1) ¼ 19.39, p < .001, /¼0.31]. In patients
with WAIS-IV FSIQ scores below 80, 100% obtained three or
more low scores (i.e. < 1 SD), whereas patients with WAIS-
IV FSIQ scores 80 or higher, 65.7% obtained three or more
scores < 1 SD [v2 (1)¼ 11.45, p¼ .001, /¼0.40]. In
patients with WAIS-IV FSIQ scores below 80, 85.3% obtained
two or more frankly impaired index scores (i.e. < 2 SDs)
compared to 40.0% of patients with WAIS-IV FSIQ scores 80
or higher [v2 (1)¼19.47, p< .001, /¼0.51].
Discussion
The goal of this study was to present clinical normative data
for the RBANS for Norwegian patients with schizophrenia
spectrum disorders, and to compare these norms with previ-
ously published norms of similar patient groups in North
America. Overall, the performance of the current patient
sample was similar to the clinical normative data for inpa-
tients and outpatients with schizophrenia disorders pre-
sented by Iverson et al. (2009) in Canada and Wilk et al.
(2004) in the United States. The average Total Scale scores
reported in these studies differed from the average Total









All patients (N¼ 335)
Mean (SD) 78.50 (20.70) 86.50 (17.34) 77.48 (17.94) 69.67 (19.47) 79.02 (20.97) 68.98 (19.09)
Median (IQR) 78.00 (66–92) 90.00 (77–102) 78.00 (66–89) 70.00 (55–83) 80.00 (70–91) 69.00 (54–82)
Skew/Kurtosis 0.08/0.36 (Y) 0.74/0.24 (N) 0.19/0.34 (N) 0.04/0.50 (N) 0.23/0.28 (N) 0.20/0.68 (N)
Men (n¼ 208)
Mean (SD) 80.80 (19.83) 88.91 (15.96) 78.87 (17.65) 71.21 (18.80) 80.41 (20.14) 71.06 (18.25)
Median (IQR) 80.00 (68–95) 90.00 (77–102) 80.00 (66–93) 72.00 (62–84) 82.00 (73–93) 71.00 (59–83)
Skew/Kurtosis 0.06/0.35 (N) 0.79/0.14 (N) 0.19/0.27 (N) 0.11/0.50 (N) 0.31/0.10 (N) 0.07/0.62 (N)
Women (n¼ 127)
Mean (SD) 74.72 (21.61) 82.55 (18.80) 75.21 (18.25) 67.14 (20.36) 76.73 (22.16) 65.57 (19.99)
Median (IQR) 75.00 (60–92) 84.00 (70–102) 78.00 (60–85) 69.00 (47–81) 80.00 (63–91) 65.00 (49–80)
Skew/Kurtosis 0.20/0.30 (Y) 0.58/0.57 (N) 0.18/0.45 (N) 0.29/0.34 (N) 0.09/0.46 (N) 0.47/0.55 (Y)
No substance abuse (n¼ 201)
Mean (SD) 78.75 (21.75) 87.33 (17.34) 76.62 (18.24) 70.04 (19.06) 79.15 (22.05) 69.53 (19.56)
Median (IQR) 78.00 (65–92) 90.00 (77–102) 78.00 (65–89) 72.00 (57–83) 80.00 (68–93) 69.00 (55–83)
Skew/Kurtosis 0.09/0.42 (Y) 0.81/0.11 (N) 0.23/0.47 (N) 0.01/0.31 (N) 0.13/0.40 (N) 0.23/0.64 (N)
Substance abuse (n¼ 134)
Mean (SD) 78.12 (19.10) 85.25 (17.33) 78.77 (17.47) 69.11 (20.14) 78.82 (19.33) 68.15 (18.41)
Median (IQR) 78.00 (66–92) 90.00 (77–102) 78.00 (66–91) 70.00 (55–83) 80.00 (73–91) 69.00 (54–81)
Skew/Kurtosis 0.05/0.31 (Y) 0.66/0.36 (N) 0.12/0.14 (N) 0.10/0.71 (N) 0.47/0.10 (N) 0.14/0.80 (N)
<High school (n¼ 196)
Mean (SD) 74.21 (20.21) 83.64 (17.70) 75.57 (16.47) 64.99 (17.56) 75.12 (21.00) 64.11 (17.70)
Median (IQR) 73.00 (60–89) 84.00 (75–102) 78.00 (65–87) 68.00 (49–77) 77.00 (63–88) 64.00 (49–77)
Skew/Kurtosis 0.15/0.43 (Y) 0.56/0.47 (N) 0.25/0.32 (N) 0.06/0.95 (N) 0.26/0.76 (N) 0.29/0.74 (N)
High school (n¼ 68)
Mean (SD) 78.79 (19.39) 87.26 (17.82) 75.37 (19.07) 69.91 (21.36) 80.60 (19.67) 69.32 (17.64)
Median (IQR) 78.00 (67–92) 90.00 (77–102) 76.50 (59–89) 71.00 (51–84) 82.00 (73–91) 71.50 (55–82)
Skew/Kurtosis 0.10/0.12 (Y) 0.93/0.09 (N) 0.23/0.72 0.26/0.25 (N) 0.34/0.27 (N) 0.04/0.63 (Y)
>High school (n¼ 71)
Mean (SD) 90.04 (18.99) 93.65 (13.53) 84.77 (19.06) 82.34 (17.02) 88.27 (19.19) 82.08 (18.08)
Median (IQR) 92.00 (75–102) 96.00 (84–102) 85.00 (75–97) 81.00 (72–94) 88.00 (74–100) 81.00 (68–96)
Skew/Kurtosis 0.15/0.40 (Y) 10.01/0.08 (N) 0.38/0.04 (Y) 0.26/0.32 (Y) 0.10/0.17 (Y) 0.00/0.82 (Y)
RBANS: The repeatable battery for assessment of neuropsychological status; SD: standard deviation; IQR: interquartile range. (Y) ¼ yes and (N) ¼ no for approxi-
mating a normal distribution based on the Kolmogorov–Smirnov test with Lilliefors Significance Correction.
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Scale score in the current sample by 0.18 (Iverson et al.,
2009) and 1.56 (Wilk et al., 2004) points. The mean Index
scores reported by (Iverson et al., 2009) differed on average
3.27 points for all five indexes; the largest difference was for
the Immediate Memory Index (8.80) and least for the
Attention Index (2.03). To our knowledge, it has not been
previously reported that Norwegian patients with schizo-
phrenia spectrum disorders have similar RBANS Index
scores to comparable patient groups in North America.
Clinical normative data allows a clinician to determine if
a patient’s cognition is worse, similar, or better than other
patients with schizophrenia spectrum disorders (Iverson
et al., 2009; Peria~nez et al., 2007; Wilk et al., 2004).
Stratifying by educational attainment and by IQ-levels pro-
vide information on expected performance when considering
the influence of these variables on test performance on the
RBANS (Gold, Queern, Iannone, & Buchanan, 1999; Iverson
et al., 2009; Wilk et al., 2004). The strong association
between level of education, NART-predicted level of intelli-
gence, and RBANS performance is not surprising. People
with schizophrenia spectrum disorders who have higher lev-
els of education might, on average, have a later disease onset
(Chen, Selvendra, Stewart, & Castle, 2018), lower levels of
psychotic symptomatology (Swanson, Gur, Bilker, Petty, &
Gur, 1998), and more cognitive reserve (de la Serna et al.,
2013; Holthausen et al., 2002).
In the current sample, women had lower scores than
men on all RBANS Indexes and the Total Scale, which also
has been reported for Australian patients (Gogos et al.,
2010), but not in samples in North America or China (Han
et al., 2012; Iverson et al., 2009; Loughland et al., 2007; Wilk
et al., 2004; Zhang, Han et al., 2015; Zhang et al., 2012).
This finding suggests that the normative tables presented
here should have considered education and intelligence
together with gender, rather than each in isolation.
However, the number of subjects would then be too few for
some categories to be representative. For example, only 26
women in the current sample have a NART-predicted level
of intelligence of  100; of those 10 had less than high
school education, 4 had completed high school, and 12 had
more than high school education. Further, the effect of gen-
der on RBANS performance was noticeably smaller than
that of education and intelligence, suggesting that educa-
tional attainment and IQ-levels might be more important
variables to consider than gender when evaluating RBANS
performance.
Table 2. Clinical normative data for patients with schizophrenia spectrum disorder: RBANS index scores corresponding to classification ranges.
Extremely low Unusually low Low average Average High average Superior
All patients (N¼ 335)
Immediate memory – 40–47 48–65 66–91 92–105 106þ
Visuospatial/Constructional 40–47 48–59 60–76 77–101 102–107 –
Language – 40–51 52–65 66–89 90–99 100þ
Attention – – 40–54 55–82 83–94 95þ
Delayed memory – 40–42 43–69 70–91 92–105 106þ
Total scale – – 40–53 54–82 83–95 96þ
Men (n¼ 208)
Immediate memory 40 41–52 53–67 68–94 95–109 110þ
Visuospatial/constructional 40–52 53–63 64–76 77–101 102–107 –
Language – 40–52 53–65 66–92 93–98 99þ
Attention – – 40–60 61–83 84–95 96þ
Delayed memory – 40–44 45–72 73–92 93–107 108þ
Total scale – 40–43 44–59 60–82 83–96 97þ
Women (n¼ 127)
Immediate memory – 40 41–57 58–92 93–99 100þ
Visuospatial/constructional – 40–53 54–69 70–102 103–107 –
Language – 40–44 45–60 61–85 86–100 101þ
Attention – – 40–45 46–81 82–93 94þ
Delayed memory – – 40–62 63–91 92–104 105þ
Total scale – – 40–48 49–79 80–93 94þ
<High school (n¼ 196)
Immediate memory – 40–43 44–58 59–88 89–99 100þ
Visuospatial/constructional 40–44 45–56 57–70 71–101 102–107 –
Language – 40–52 53–60 61–87 88–95 96þ
Attention – – 40–47 48–77 78–88 89þ
Delayed memory – – 40–58 59–88 89–101 102þ
Total scale – – 40–48 49–77 78–90 91þ
High school (n¼ 68)
Immediate memory – 40–46 47–66 67–92 93–109 110þ
Visuospatial/constructional – 40–58 59–76 77–102 103–107 –
Language – 40–42 43–58 59–89 90–101 102þ
Attention – – 40–49 50–83 84–97 98þ
Delayed memory – 40–46 47–72 73–90 91–104 105þ
Total scale – 40–41 42–53 54–81 82–90 91þ
>High school (n¼ 71)
Immediate memory 40–53 54–65 66–74 75–101 102–120 121þ
Visuospatial/constructional 40–59 60–69 70–83 84–102 103–107 –
Language – 40–57 58–72 73–97 98–109 110þ
Attention – 40–64 65–70 71–93 94–105 106þ
Delayed memory 40–44 45–69 70–74 75–99 100–118 119þ
Total scale 40–50 51–60 61–67 68–96 97–105 106þ
RBANS: The repeatable battery for assessment of neuropsychological status.
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The base rates information presented in Table 3 facilitates
the interpretation of all five RBANS index scores simultan-
eously in patients with schizophrenia spectrum diagnoses.
Having several low Index scores is common. For example,
79.1% had two or more Index scores more than one SD below
the mean, 63.3% had two or more Index scores at or below
the 5th percentile, and 40% had two or more Index scores
below two SDs. These findings are fairly similar to those
reported by Iverson et al. (2009). Higher base rates of low
RBANS Index scores were more common for patients with
lower education and lower intellectual abilities, as reported in
previous studies (Iverson et al., 2009; Wilk et al., 2004).
The present RBANS normative data provide information
regarding performance on the RBANS for Norwegian
patients with schizophrenia spectrum disorders. This infor-
mation is important for clinicians. Demonstrating that a
patient with a schizophrenia spectrum disorder has cognitive
deficits is useful, but to further differentiate whether the def-
icit is severe, moderate, or mild compared to other patients
in the same diagnostic group might allow for more precise
and better targeted treatment and rehabilitation decisions
(Iverson et al., 2009; Peria~nez et al., 2007; Wilk et al., 2004).
The RBANS has been used to measure cognitive impair-
ment in schizophrenia spectrum disorders in North
America, Europe, and Asia (Anda et al., 2016; Azizian,
Yeghiyan, Ishkhanyan, Manukyan, & Khandanyan, 2011;
Chianetta, Lefebvre, LeBlanc, & Grignon, 2008; de Girolamo
et al., 2014; De la Torre et al., 2016; Dickerson et al., 2004;
Ehrenreich et al., 2007; Gogos et al., 2010; Gold et al., 1999;
Halasz, Levy-Gigi, Kelemen, Benedek, & Keri, 2013; Han
et al., 2012; Harris et al., 2004; Helle et al., 2014; Hobart
et al., 1999; Iverson et al., 2009; Juhasz, Kemeny, Linka,
Santha, & Bartko, 2003; Kelemen, Kiss, Benedek, & Keri,
2013; Loughland et al., 2007; Raudeberg et al., 2019; Sanz,
Vargas, & Marın, 2009; Takeuchi et al., 2013; Wang et al.,
2019; Wilk et al., 2004; Zhang, Han et al., 2015; Zhang, Li
et al., 2015; Zhang et al., 2012, 2018). It might be helpful to
replicate the present study (Iverson et al., 2009 and Wilk
et al., 2004) in a few more countries to extract common
themes of impairment in schizophrenia spectrum disorders
across cultures. In particular, educational attainment seems
important for assessing the clinical meaningfulness of
RBANS scores in Canada, the U.S., and in Norway. This
effect might be more or less pronounced in other countries,
because educational systems differ substantially between
nations. Also, gender differences in performance on the
RBANS might be important in schizophrenia spectrum dis-
orders, but as shown in the current study, gender differences
in Norway are not similar to findings in North America but
seem more similar to findings in Australia (Gogos et al.,
2010). The main point is that cognitive impairment might
differ somewhat across cultures and might have different
impact on functional outcome.
Conclusions
The present study showed that Norwegian patients with
schizophrenia spectrum disorders have cognitive deficits
similar to patient populations in North America and that
these measures of deficits have a similar distribution of
severe, moderate, mild, and no impairment. RBANS Index
scores varied by gender, education, and IQ within people
with schizophrenia spectrum disorders, but not by comorbid
substance abuse in the present sample. Stratified clinical
normative values, such as those presented in the current
study, can be useful when assessing individual patients’
neuropsychological profiles. This is important when plan-
ning treatment and rehabilitation programs.
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